🇺🇸 FDA
Pipeline program

ACP-211

ACP-211-002

Phase 2 small_molecule active

Quick answer

ACP-211 for Major Depressive Disorder (MDD) is a Phase 2 program (small_molecule) at ACADIA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
ACADIA PHARMACEUTICALS INC
Indication
Major Depressive Disorder (MDD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials